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ABSTRACT
A NOVEL PERIPLASMIC PROTEIN INVOLVED IN THE ELONGATION STEP OF
LIPOMANNAN AND LIPOARABINOMANNAN BIOSYNTHESIS IN MYCOBACTERIUM
SMEGMATIS
FEBRUARY 2017
STEPHANIE ALLEN HA, B.S. UNIVERSITY OF CONNECTICUT
M.S. UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Dr. Yasu S. Morita

Mycobacteria are atypical bacteria possessing unusual cell envelopes comprised of
an outer membrane, covalently linked to an arabinogalacatan-peptidoglycan
structure via waxy mycolic acids, in addition to the conventional inner membrane.
This thick and highly impermeable cell envelope is a major deterrent to antibiotic
treatment of clinically relevant mycobacterial pathogens, including Mycobacterium
tuberculosis (Mtb), which infects a third of the world’s population and kills millions
each year. Thus, the regulation of mycobacterial cell envelope biosynthesis is of
great interest for the development of more effective therapeutics for treating Mtb
infections. Using the model organism Mycobacterium smegmatis (M. smegmatis), we
identified a novel protein, Spe2, with an unknown role in the biosynthesis of the cell
envelope glycolipids lipomannan (LM) and lipoarabinomannan (LAM). Based on the
observation that Δspe2 mutants produce truncated LM/LAM, I speculated Spe2
might enhance the elongation of these products. Here, I use biochemical assays to
show Spe2 is localized to the periplasm where it can directly interact with the
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LM/LAM biosynthetic pathway. I further utilize a genetic approach to demonstrate
that Spe2 acts at the stage in which the mannosyltransferase MptA mediates
periplasmic LM elongation. Moreover, native polyacrylamide gel electrophoresis
(PAGE) and co-immunoprecipitation techniques failed to reveal Spe2 protein
binding partners. Together, these data suggest Spe2 is a periplasmic protein
involved in regulating LM/LAM biosynthesis, perhaps through direct interactions
with LM intermediates.
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CHAPTER 1
BACKGROUND AND SIGNIFICANCE
1.1

Mycobacteria and Disease
The genus Mycobacterium consists of a diversity of sturdy microorganisms,
of which many are important clinical and veterinary pathogens (1, 2). Major
mycobacterial species of clinical relevance are outlined in Table 1. Mycobacterium
tuberculosis (Mtb) is perhaps the most prominent of these organisms, although
Mycobacterium leprae has historically been problematic for humans as well (2, 3).
These pathogenic species of mycobacteria are generally slow growers; Mtb, for
example, has a generation time of up to to 24 hours (4). This slow growth makes
culturing for diagnostics and research particularly difficult. As a result,
Mycobacterium smegmatis (Msm) is a fast-growing saprophytic commensal
commonly used as a model organism in place of these slow growers. Additionally,
cloning in mycobacteria has greatly expanded due to the creation of strains
engineered for efficient transformation, including the mc2155 strain of Msm that is
now referred to as “wild-type” Msm (5). These Msm strains can be used to study
mycobacterial physiology and other cellular processes to gain a solid foundation
prior to studying these concepts in Mtb.

1.2

Tuberculosis
Tuberculosis (TB) is the outcome of human infection with Mtb, an obligate
aerobic bacterium characterized by slow-growth, fastidiousness, and an unusual
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acid-fast cell wall (6). Mtb infects a third of the world’s population—killing millions
annually (7). In fact, despite improvements in controlling TB, Mtb killed 1.4 million

Table 1. Characteristics of Clinically Important Mycobacteria*
Organism

Reservoir

Main Disease Caused in Humans

Mycobacterium tuberculosis

Human

Tuberculosis

Mycobacterium leprae

Human

Leprosy

Mycobacterium ulcerans

Environment

Skin ulcerations

Mycobacterium bovis

Animals

Tuberculosis

Mycobacterium marinum

Water, Fish

Skin granuloma

Mycobacterium avium

Environment

Tuberculosis-like

*Adapted from Schaechter’s Mechanisms of Microbial Disease (p.259) by N.
Engleberg, T. Dermody, and V. DiRita (Eds), 2013, Baltimore, MD: Lippincott
Williams & Wilkins.

individuals in 2015 alone (7). Most Mtb infections are considered latent, in which
the bacteria are suppressed by the immune system. However, active infection, in
which Mtb is not contained, occurs in individuals with weakened immune systems
and represents roughly 5-15% of TB cases (7).

Moreover, pulmonary TB is

concurrent with the human immunodeficiency virus (HIV) epidemic, meaning those
infected with HIV are prone to Mtb infection. In 2015 alone, the World Health
Organization (WHO) has reported that 0.4 million HIV-positive individuals died of
Mtb infection (7).
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Drug resistance in Mtb has been on the rise, with multi-drug resistant TB
(MDR-TB) and extremely drug resistant TB (XDR-TB) steadily emerging (8, 9). This
complicates the already lengthy and toxic treatment regimen of first-line and
second-line antibiotics (10). Thus, there is a great need for the development of new
treatments to combat TB infection. Recently, mutations in cell envelope glycolipid
biosynthetic pathways have been shown to increase mycobacterial antibiotic
sensitivity while simultaneously diminishing cell wall integrity (11). These studies
implicate the mycobacterial cell envelope as a promising drug target for novel
therapeutic strategies in treating TB infection.
1.2.1 Pathogenesis
1.2.1.1

Encounter

Mycobacteria are naturally abundant in the environment. However, in the case of
Mtb, humans are the natural reservoir (4, 12). Aerosolized droplets produced from
the coughs of an infected individual are the mechanism of spread from person to
person. The infectious dose (ID50) of Mtb is estimated to be a range within 1-200
organisms required to establish an infection (13, 14).
1.2.1.2

Invasion

Within the alveoli of the lungs, Mtb primarily infects resident alveolar macrophages,
although other immune cells such as dendritic cells and alveolar epithelial type II
pneumocytes are potential first contacts as well (15). Mtb utilizes a number of
strategies to enhance its uptake into these macrophages, including the use of
3

complement factors, surfactants, and antibody-mediated opsonization (16).
Primarily, non-opsonic intake via contact with mannose receptors on macrophages,
which can be upregulated by the presence of the glycoprotein surfactant protein A
in the alveolar environment, increases Mtb binding and promotes phagocytosis (15,
16). Another route of entry into macrophages is through recognition of pathogen
associated molecular patterns (PAMPs)—better known as microbial associated
molecular patterns (MAMPs)—by Toll-like receptor 2 (TLR2). TLR2 activation,
which in turn enhances CD14 affinity to Mtb, further increases the pathogen’s
uptake. Opsonic methods of internalization, such as complement receptor 3 (CR3),
or FC-γ receptors (FCγRs) which also promotes host production of proinflammatory mediators, are utilized by Mtb (16). The fact that Mtb is capable of
using various routes of entry highlights the pathogen’s ability to readily compensate
with alternative mechanisms.
1.2.1.3

Establishment of infection

Once Mtb is phagocytosed, the bacterium resides in a phagosome which later fuses
with a lysosome to create a highly acidic and degradative environment. However,
Mtb possesses clever strategies to impede phagosome maturation by interfering
with the Ca2+, calmodulin, phosphoinositide 3-kinase (PI3K) signaling cascade. This
prevents both ATPase incorporation into the phagosome, rendering it unable to
create an acidic environment, and the delivery of lysosomal hydrolases to degrade
Mtb (16, 17). In addition to blocking phagosome maturation, Mtb also is capable of
impeding apoptosis and interfering with antigen presentation. For instance, the
4

serine hydrolase Hip1 is known to inhibit the expression of major histocompatibility
complex II (MHC II) which is used by macrophages and dendritic cells to present
antigens (16). Mtb also forces the infected macrophage to sequester MHC II through
the reduction of the host protease cathepsin S, which results in the simultaneous
reduced export of mature MHC II and increased export of immature MHC II (16). As
a result, these strategies directly affect antigen-presenting cells and ultimately slow
down the progression of the adaptive immune response for increased Mtb survival.
1.2.1.4

Role of PIMs/LM/LAM in TB Pathogenesis

The phosphatidyl-inositol (PI) based glycolipids including PI-mannosides (PIMs),
lipomannan (LM), and lipoarabinomannnan (LAM) are abundant on mycobacterial
cell envelopes. These glycolipids are important immunomodulatory molecules that
aid in Mtb invasion and survival in the host on multiple fronts. Mannose-capped
LAM, or ManLAM, binds to mannose receptors on the macrophage, enhancing Mtb
internalization (16). However, structural differences in ManLAM, such as more or
less branching, between species and strains have been noted to alter the affinity of
Mtb attachment to macrophages (18). ManLAM additionally binds to Dectin-2 and
dendritic cell specific intercellular adhesion molecule 3 grabbing non-integrin (DCSIGN) in dendritic cells to elicit TNF-α, IL-6, and IL-10 secretion (19). DC-SIGN and
mannose receptor mediated binding appears to be contingent on recognition of the
mannose cap of ManLAM, as PI-capped LAM (PILAM) is not recognized by these
receptors (20–22). ManLAM also blocks PI3K recruitment to the phagosome, which
inhibits phagosome maturation and enables Mtb survival as described above (16).
5

Furthermore, PIMs, LM, LAM are TLR2 agonists that induce pro-inflammatory
responses, such as the production of pro-inflammatory cytokines IL-10, TNFα, that
ultimately cause host damage (16, 17, 23). The acylation of PIMs also appears to be
an important factor for TLR2 activation (24). Interestingly, Mtb phoP mutants
lacking the transcriptional regulator PhoP possess a greater proportion of
monoacylated ManLAM and decreased multi-acylated ManLAM (25). Interference of
lipid raft signaling, also key to phagosome maturation, is also thought to occur, since
TLR2 activation also leads to increased Mtb binding to CD14 via LAM (26). Both LM
and LAM have been shown to incorporate into lipid rafts, which can be blocked by
the addition of PIMs (27). Additionally, PIMs, LM, and ManLAM can induce early
stage granuloma formation, presumably through TLR2 activation—although this
has not been demonstrated (23).
It is important to note that during studies of LAM-induced immunological response
in the host, the cell line used and method of preparation of LAM both affect the
maturation and cytokine profiles, and appears to be the cause of confusing cytokine
profiles published throughout the literature (18). Despite this, it is clear that
clinically isolated Mtb strains induce greater TNF production in human
macrophages compared to the virulent laboratory strain H37Rv, while H37Rv
causes increased TNF production compared to attenuated H37Ra (18).
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1.3

Mycobacterial Cell Structure: Atypical Bacteria with Unusual Cell Walls

1.3.1 Overview of Arrangement and Components
Mycobacteria possess an unusual cell envelope which contains an inner
membrane and an arabinogalactan-peptidoglycan (AG-PG) layer, in addition to a
mycomembrane (Figure 1). The mycomembrane consists of an outer membrane
along with its associated glycolipids, free lipids, and waxy mycolic acids, which are
covalently linked to the AG-PG structure (6, 28). This mycolyl arabinogalactanpeptidoglycan (mAGP) complex is considered the mycobacterial cell wall core—an
insoluble structure critical to cell viability (6).
Furthermore, the presence of phospholipids such as phosphatidylinositol
(PI), which is typically found in eukaryotic cells, is rather unusual in bacteria. The
PI-based glycolipids include PI mannosides (PIMs), lipomannan (LM), and
lipoarabinomannan (LAM), which will be discussed further below.
1.3.2 Biosynthesis of PIMs/LM/LAM
PIMs, LM, and LAM originate from the same initial pathway (Figure 2). PI on
the inner membrane is acylated and has sequential mannose additions in a few
major steps. First, the essential enzyme, MSMEG_2935 or PimA, adds the first
mannose by transferring the residue from the mannose donor GDP-Man, resulting in
the precursor PIM (29–31). This structure can next be modified into AcPIM2 when
the acyltransferase phosphatidyl-myo-inositol mannosides acyltransferase A, or
PatA, transfers a fatty acid to the PIM (31, 32), followed by MSMEG_4253, or PimB’,
7

mediated mannose addition (31). The reverse reaction (formation of PIM2 followed
by PatA acylation) is also thought to occur, but with lower preference (31). From
AcPIM2, sequential mannoses are further added, with products AcPIM3 through
AcPIM6 receiving mannoses from the mannose donor polyprenol-phosphate
mannose (PPM) rather than GDP-Man (33–35).
The intermediate AcPIM4 is considered a branching point, in which it
becomes the substrate for either PimE (MSMEG_5149), which transfers the fifth
mannose to produce the final PIM product AcPIM6 (34), or the first (unidentified in
Msm) mannosyltransferase of the LM/LAM biosynthetic pathway which begins the
elongation of a mannose backbone via α1,6 linkages (11, 36–38). The
mannosyltransferase MSMEG_4241, or MptA, further elongates the LM intermediate
through α1,6 linkages to form mature LM, which possesses up to 34 mannose
residues (11, 36). Simultaneously, the mannosyltransferase MSMEG_4247, or MptC,
branches this backbone by addition of mannoses via α1,2 linkages (38). The
expression levels of MptA and MptC seem to regulate the length of the mannan
chain, as the overexpression of MptC results in shorter LM and LAM whereas the
overproduction of MptA causes longer LM and LAM to be formed (38). Another
potential mechanism for the regulation of LM and LAM production is through the
lipoprotein LpqW (MSMEG_5130), which has been suggested to help channel
AcPIM4 towards LM/LAM biosynthesis (39–42).
While LM is also a major end product, LAM is thought to be produced from
LM through the addition of arabinose residues by the chain extending
8

arabinofuranosyltransferase

EmbC

(43,

44).

EmbC

(Mtb:

Rv3793,

Msm:

MSMEG_6387) is essential in Mtb, but not in Msm, which supports the importance of
LAM in Mtb pathogenesis (44). AftC (MSMEG_2785) and AftD (MSMEG_0359), in
which

the

latter

is

interestingly

essential

only

in

Msm,

are

α1,3

arabinofuranosyltransferases with roles in both LAM and arabinogalactan
biosynthesis (45–47). Mtb and other slow growing pathogenic mycobacteria seem
to have LAM that is additionally capped with terminal mannose residues (ManLAM)
(48) whereas Msm LAM is capped with a PI moiety (PILAM) (49). These differences
implicate the contribution of ManLAM in pathogenesis.
Interestingly, Ppm1 (MSMEG_3859) and Ppm2 (MSMEG_3830) are essential
enzymes that form the PPM synthase found in the plasma membrane tightly
associated with cell wall (PM-CW), whereas PimB’ and AcPIM2 can be found in the
plasma membrane free of cell wall (PMf, now termed inner membrane domain
(IMD)), suggesting that mycobacteria spatially regulate the PIMs pathway (35, 50,
51). Additionally, the LM/LAM biosynthetic enzymes are all polytopic membrane
proteins, suggesting LM and LAM are first made in the periplasm prior to transport
to the outer membrane by an unknown mechanism.
1.4

Spe2: A Novel Cell Envelope Protein Involved in LM/LAM Biosynthesis
Previously, a forward genetic screen of pimE suppressor mutants identified a
novel gene, which we termed spe2, involved in LM/LAM biosynthesis (Rahlwes et al.
in preparation) identified by whole genome sequencing of three of these suppressor
mutants (S1, S10, and S22) (Figure 3). Each mutant had specific point mutations,
9

with the exception of S22 which had a transposon insertion, in conserved regions of
this gene (Figure 3). Further characterization of these isolates showed that these
were suppressor mutants which still lacked AcPIM6 (Figure 4a), indicating that
pimE was not restored. However, the LM/LAM profiles of the mutants had similar
shifts in size compared to that of WT (Figure 4b). Upon complementation with Spe2,
the LM/LAM profile of each mutant was restored to the WT profile (Figure 4b). To
ensure that the mutations in spe2 were indeed causing these changes in LM/LAM, a
Δspe2 Msm strain was generated and characterized. This Δspe2 mutant had similar
smaller LM/LAM as seen in each of the suppressor mutants, which was also restored
by complementation with Spe2-HA under the control of either a hsp60 promoter or
the endogenous promoter (Figure 5). These data suggest that Spe2 is somehow
implicated in LM/LAM biosynthesis.
To better understand the function of Spe2, simple bioinformatic analyses
were conducted. The transmembrane prediction using Hidden Markov Models
(TMHMM) predict Spe2 to be a β-sheet rich protein with one transmembrane
domain (52). A recent study by Song et al. 2008 predicted the Spe2 homolog in Mtb
(Rv0817c) to be an outer membrane protein (53). However, it should be noted that
the presence of signal peptide sequences in a protein can be mistaken as a
transmembrane domain in many predictive algorithms, making outer membrane
protein prediction difficult. Indeed, Spe2 possesses a signal sequence, suggesting
Spe2 is an extra-cytoplasmic protein (54). This signal sequence accounts for the
predicted transmembrane domain and may indicate that Spe2 is an exported
10

protein. This speculation is further supported by sucrose density gradient
fractionation data that demonstrate Spe2-HA localizes to the plasma membrane
tightly associated to the cell wall (PM-CW) (Figure 6).
Based on these preliminary data, I hypothesized that Spe2 might be
influencing LM/LAM biosynthesis by enhancing the activities of the elongation
mannosyltransferase directly involved in this pathway. Since LM/LAM biosynthesis
occurs in the periplasm, Spe2 might be a periplasmic regulator that directly
interacts with these elongases. Furthermore, understanding the role of Spe2 in the
regulation of PIMs/LM/LAM biosynthesis may lead to novel strategies in the
development of TB therapeutics.
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CHAPTER 2
MATERIALS AND METHODS
2.1

Bacterial Strains and Culture Conditions
M. smegmatis mc2155 and derived mutants (see Table 2) were grown at 30°C
in Middlebrook 7H9 (BD) supplemented with 10% DC (11 mM glucose and 14.5mM
NaCl), and 0.05% Tween-80, or at 37°C on Middlebrook 7H10 agar supplemented
with 10% DC unless otherwise indicated. Antibiotics were added to the media at the
following concentrations: 100μg/ml hygromycin (Wako), 20μg/ml streptomycin
(Fisher Scientific), and 20 μg/ml kanamycin (MP Biologicals).
Table 2. Strains
Strain

Genus

mc2155

Species

Description

Reference

Mycobacterium smegmatis

WT

Snapper et al. 1990

SUMA
178

Mycobacterium smegmatis

Δspe2

Rahlwes et al. (in
preparation)

SUMA
188

Mycobacterium smegmatis

Δspe2::Spe2-HA (Phsp60)

Rahlwes et al. (in
preparation)

SUMA
228

Mycobacterium smegmatis

Δspe2::Spe2-HA (Pnative)

Rahlwes et al. (in
preparation)

SUMA
210

Mycobacterium smegmatis

Δspe2::T7-Spe2-HA
(Phsp60)

Rahlwes et al. (in
preparation)

SUMA 26

Mycobacterium smegmatis

GlnA1-HA; Transfected
with pMUM015

Hayashi et al. 2016

SAB 571

Mycobacterium smegmatis

Transfected with
pYAB133 and pYAB 288

Fukuda et al. 2013

SUMA
227

Mycobacterium smegmatis

Transfected with
pYAB133 and pYAB 288

This study

Escherichia

XL-10 Gold chemically
competent cells

Hanahan et al.
1991

coli
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2.2

Establishment of Recombinant Mycobacterium smegmatis Strains
Plasmids (see Table 3) were transformed into chemically competent
Escherichia coli (E. coli) during heat shock at 42°C for 45 seconds followed by
incubation at 37°C for 1 hour to allow for antibiotic expression prior to plating.
Plasmids were purified and transfected into electrocompetent mycobacteria.
Table 3. Plasmids.

2.3

Plasmid Name

Description

Selection

Reference

pYAB133
(pTEK-4S0X)

revTet repressor expression
vector (episomal)

Kan

Guo et al. 2007

pYAB288

Tet-off 4241 (MptA) expression
vector (integrated)

Hyg

Guo et al. 2007

pYAB156

Integration vector with multiple
coding sequences downstream
Kan
of hsp60 promoter

Gift from William R.
Jacobs Jr.

pMUM015

GlnA1-HA expression vector
(integrated)

Hayashi et al. 2016

Hyg

Preparation of Cell Lysates, SDS-PAGE, and Western Blot Analysis
Mycobacteria were grown at 30°C until log phase (OD600 0.5-1), at which 50
OD units (50/OD600) were harvested by centrifugation at 3220 x g for 10 minutes at
4°C (Eppendorf 5810R). Cells were washed twice with 50 mM Hepes-NaOH (pH 7.4)
(MP Biologicals). Pellets were resuspended at 200 mg wet pellet weight/ml in lysis
buffer containing 25 mM Hepes-NaOH (pH 7.4), 15% glycerol, 2 mM EGTA, and
protease inhibitor (Pierce). 0.5 ml of this cell suspension was transferred to a 2 ml
screw cap tube containing 400 mg glass beads (Sigma) and lysed at 4°C using a
BeadBug Microtube Homogenizer (Benchmark Scientific) at 4,000 rpm for 5 cycles
13

each consisting of 30 seconds of homogenization followed by 1 minute incubations
on ice. Cellular debris was removed by centrifugation at 100 x g for 5 minutes at 4°C
(Eppendorf 5418R). The supernatant was centrifuged at 4°C for 10 minutes at 800 x
g, followed by a 2,200 x g centrifugation for the same duration. The resulting protein
fraction was processed for SDS-PAGE by mixing with 4X reducing loading buffer
(laemmli buffer) and run on 12 or 15% gels as indicated. Proteins were blotted onto
a polyvinylidene difluoride membrane (PVDF) (BioRad). The membrane was
blocked for at least 1 hour in 5% milk in phosphate buffered saline containing 0.1%
Tween-20 (PBST). To visualize the following epitopes, the following primary and
secondary antibodies were used as indicated in Table 4. Bound probes were
visualized by chemiluminescence and captured using ImageQuant LAS 4000 mini
(GE Healthcare).
Table 4. Antibodies.
Primary
Antibody

Manufacturer
/Reference

Dilution

Secondary
Antibody

Manufacturer
/Reference

HA

Sigma

1:1000
(1h)

Anti-mouse HRP
conjugate IgG

Amersham

1:1000
(1h)

FLAG

Sigma

1:5000
(O/N)

Anti-mouse HRP
conjugate IgG

Amersham

1:10,000
(1h)

MptA

Sena et al.
2010

1:2000
(1h)

Anti-rabbit HRP
conjugate IgG

Amersham

1:1000
(1h)

MptC

Sena et al.
2010

1:2000
(1h)

Anti-rabbit HRP
conjugate IgG

Amersham

1:1000
(1h)

Mpa

Darwin et al.

1:2000

Anti-rabbit HRP

Amersham

1:2000

2004

(1h)

conjugate IgG

14

Dilution

(1h)

2.4

Immunoprecipitation
HA7 agarose beads (Sigma) were washed with HES (25 mM Hepes-NaOH (pH
7.4), 2 mM EGTA, 150 mM NaCl) or HEST (25 mM Hepes-NaOH (pH 7.4), 2 mM
EGTA, 150 mM NaCl, 1% Triton-X100) for a total of five times. Bead beating cell
lysate was added to these pre-washed beads, and incubated with HES or HEST
buffer at 4°C overnight under gentle rotation at 5 rpm. Beads were washed with HES
or HEST buffer five times prior to elution with HA peptide (AnaSpec Inc) at 30°C.
Anti-HA elutions were run on 12% reducing SDS-PAGE and visualized via western
blot as described above.
For use of Protein A magnetic beads (Fisher), 36 µl of bead-beating lysate
was incubated with ~5 µg of primary antibody with bead-beating lysis buffer with
protease inhibitor (described previously) in a total volume of 500 µl for 1 hour at
room temperature with gentle mixing prior to addition to Protein A magnetic beads
pre-washed in tris-buffered saline (TBS) containing 0.05% Tween-20 and 0.5 M
NaCl (TBS wash buffer). Sample was then incubated with the beads for 1 hour at
room temperature with gentle mixing. The magnetic beads were separated from the
flow through with a magnetic stand, then washed with the TBS wash buffer. Beads
were resuspended in 15 µl 4X reducing loading buffer (laemmli buffer) and boiled
for 10 minutes. Beads were separated from eluate on a magnetic stand and eluate
was immediately analyzed by SDS-PAGE.

15

2.5

Proteinase K Accessibility Assays
Cultures were grown to log phase in 7H9 then harvested for 50 OD units.
Cells were washed in 1 ml phosphate buffered saline (PBS) then resuspended in 5
ml PBS containing 40% sucrose. 1.5 ml aliquots were removed. To each aliquot, 5
mM DTT (MP Biologicals) and 1 mg/ml Proteinase K (Fisher) was added. Proteinase
K was not added to untreated controls. Samples were then incubated for 1 or 2
hours at 37°C shaking. To stop Proteinase K activity, 2 mM PMSF (Sigma) was added
directly to the samples. Samples were then washed twice in PBS containing protease
inhibitor. Proteins were either recovered by incubation at 37°C with 1% SDS for 30
minutes followed by boiling for 10 minutes, or resuspended at 200 mg wet pellet/ml
PBS containing protease inhibitor and subjected to bead-beating lysis as described
above.
For lysozyme and glycine weakening of the cell wall, cultures were grown in
7H9 until log phase, then ~43 OD units was harvested. Cells were washed in 1ml
PBS, then resuspended in either 500µl of PBS or PBS containing 50 µg/ml lysozyme
and 1.2% glycine. Samples were incubated at 37°C shaking for 3.5 hours. 0.1 mg/ml
or 1 mg/ml of Proteinase K was added directly to the samples and incubated at 37°C
shaking for 3 hours. Untreated controls did not receive Proteinase K. 2 mM PMSF
was added to the samples, which were subsequently homogenized by bead-beating
lysis.

16

2.6

Lipid/LM/LAM Extraction and Analysis
WT cultures were grown to log-phase. Knockdowns of SAB571 and SUMA
227 were induced with 40 ng/ml anhydrotetracyline (atc) at the time of inoculation
and timepoints were taken at log (18-24 hours), stationary (44-48 hours), and late
stationary (68-72 hours) phase. Lipids were sequentially extracted twice with
chloroform-methanol (2:1, vol/vol) and once with chloroform-methanol-water
(1:2:0.8, vol/vol/vol). The resulting aqueous phase (PIMs and other lipids) was
subject to drying under a nitrogen stream followed by 1-butanol-water (2:1,
vol/vol) partitioning, while the pellet (LM/LAM) was subject to phenol-water (1:1,
vol/vol) extraction at 55°C for 2 hours. Phospholipids and PIMs were analyzed by
HPTLC (Millipore) in chloroform-methanol-13M NH3-water (180:140:9:9:23) and
visualized by orcinol (PIMs) or molybdenum blue (phospholipids). LM/LAM was
run on 15% or 20% (where specified) reducing SDS-PAGE and visualized with ProQ
Emerald 488 Glycoprotein Gel and Blot Stain Kit (Molecular Probes).

2.7

MALDI-TOF MS Analysis
LM/LAM hot phenol extracts were further purified via ocytl-Sepharose
column chromatography (GE Healthcare) and lyophilized. 0.5 µl of the octylSepharaose purified LM/LAM was mixed with 0.5 µl of matrix solution (20 mg/ml
sinapinic acid (SA), 30% acetonitrile, 1% trifluoroacetic acid (TFA) in water).
Samples were analyzed on a Bruker Microflex MALDI-TOF instrument (Bruker
Daltonics) using linear mode and positive ion detection.
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CHAPTER 3
RESULTS
3.1

Subcellular Localization of Spe2
Based previous observations that LM and LAM are both smaller in a Δspe2 M.
smegmatis (Msm) mutant, we speculate Spe2 may regulate LM/LAM biosynthesis. To
test this hypothesis, the subcellular localization of Spe2 first needed to be
determined. Since LM/LAM biosynthesis takes place in the periplasmic space, Spe2
must be a periplasmic protein or an inner membrane protein with a periplasmic
face in order to interact with components of this pathway.
In order to identify Spe2 as a periplasmic associated protein, I must confirm
that Spe2 is not a cytoplasmic protein. Approaches including immunoprecipitation
(IP) and other protease accessibility assays were utilized to address this question
regarding the localization of Spe2.
Immunoprecipitation of Spe2-HA from Whole Cell Lysate
To distinguish between cytoplasmic or periplasmic localization of Spe2, I
performed anti-HA IP of whole cell lysates from a C-terminal HA-tagged Spe2 strain
of Msm and a C-terminal HA-tagged GlnA1 (MSMEG_4290) Msm strain. GlnA1, an
established cytoplasmic protein (50), was successfully pulled down with anti-HA
agarose beads (Figure 7b). Conversely, Spe2-HA was not pulled down under the
same conditions (Figure 7b). These results indicate Spe2 might not be a cytoplasmic
protein. I then considered the possibility that, if Spe2 is a periplasmic protein, the
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HA epitope would not be accessible by the beads due to the inner membrane acting
as a barrier. With this in mind, anti-HA IP of Spe2-HA was performed in the
presence of the mild, nonionic detergent TritonX-100 to help disrupt the inner
membrane (Figure 7a). Under this condition, Spe2-HA was successfully precipitated
from cell lysates (Figure 7b). The inaccessibility of the HA tag on Spe2 in the absence
of detergent implies that the tag is blocked by the inner membrane—a barrier that
is absolved with the addition of mild detergent. Thus, these IP results coincide with
the idea that Spe2 is a periplasmic protein.
3.1.1 Immunoprecipitation from Whole, Intact Cells
To further distinguish the localization of Spe2, IP was performed on whole,
intact cells to assess potential surface exposure. Periplasmic and cytoplasmic
proteins should not be accessible to anti-HA beads in whole cells, even with the
addition of detergent, due to the intact mAGP core. Indeed, using the same IP
procedure as described above with whole, intact cells, Spe2-HA was not pulled
down even with the addition of 1% TritonX-100 (Figure 8a). However, a proper
outer membrane protein control is necessary to validate such a technique. Thus, I
generated a strain of Msm expressing FLAG-tagged Mtb12 (MSMEG_3903), one of a
number of predicted Msm outer membrane proteins as described by He and De Buck
et al. 2010 (55). In order to use the same IP system to pull down both FLAG and HA
tagged proteins, I utilized protein A magnetic beads pre-incubated with the
respective antibodies to IP outer membrane proteins from intact cells.
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van der Woude et al. 2013 describe a method by which Mycobacterium
marinum (M. marinum) outer membrane proteins can be selectively extracted from
fractionated cell lysates with the non-ionic detergent n-octyl-β-D-glucopyranoside
(OBG) (56). A similar detergent of the same family has also been described in the
literature for selective extraction of the Msm outer membrane porin MspA (57).
Thus, I reasoned that outer membrane proteins on whole, intact cells could be more
accessible to antibodies with the presence of mild detergent—particularly OBG. In a
pilot experiment, incubation with 1% OBG for one hour at room temperature was
the optimal condition for pulling down Mtb12-FLAG from whole, intact cells (Figure
8b, right panel; Supplemental Figure 3). Unfortunately, while Mtb12-FLAG was
successfully immunoprecipitated from whole intact cells the first three of five total
experimental replicates, the last two attempts were unsuccessful. As expected,
neither Spe2-HA nor GlnA1-HA was pulled down from intact cells in the presence of
OBG (Figure 8b, left panels). The lack of recovery of Spe2-HA from intact cell IP
suggests Spe2-HA is not an outer membrane protein. However, the unsuccessful
attempt to pull down Mtb12-FLAG in the same experiment confounds this result.
3.1.2 Protease Accessibility in Intact Cells
Protease accessibility assays are frequently used in the literature to
determine surface exposure of proteins. This procedure utilizes Proteinase K, a nonspecific protease that cleaves peptide bonds, to degrade proteins on the surface of
intact cells. During short Proteinase K treatment, surface exposed proteins are
degraded while cytoplasmic and inner membrane proteins remain intact. Additional
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published measures such as the use of phosphate buffered saline (PBS) containing
40% sucrose and the presence of dithiothreitol (DTT) were included in order to
maximize efficiency of Proteinase K treatment (55, 58). Proteins were solubilized
with 30 minutes of 1% SDS incubation and subsequently boiled for western blot
analysis.
Within two hours of 1 mg/ml Proteinase K treatment, the outer membrane
control Mtb12-FLAG was degraded in intact cells (Figure 9a). This disappearance of
Mtb12-FLAG is only seen when I carefully titrated the protein loading onto the SDSPAGE gel, emphasizing the significant impact of over-expression of Mtb12-FLAG on
Proteinase K digestion. Neither Spe2-HA nor GlnA1-HA were recovered, even in the
untreated samples (Figure 9b). Proteinase K activity was confirmed during
treatment of lysate, in which all three proteins were degraded upon addition of 1
mg/ml Proteinase K (Figure 9 a and b). Therefore, I concluded the lack of recovery
of Spe2-HA and GlnA1-HA from both untreated and treated samples was due to 1%
SDS as a poor method for solubilizing internal proteins. In order to address this
issue, the experiment was scaled up so the samples could be homogenized through
bead-beating lysis, which should improve protein recovery. Using this method,
Spe2-HA and GlnA1-HA were both recovered from untreated samples, proving the
validity of this experimental method (Figure 9c). Spe2-HA was not degraded after
two hours of Proteinase K treatment in intact cells (Figure 9c). Similarly, the
cytoplasmic protein GlnA1-HA was not degraded in intact cells under the same
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conditions (Figure 9c). Mtb12-FLAG, however, does not appear to be degraded in
this experiment (Figure 9c).
3.1.3 Protease Accessibility of Spe2 in Lysozyme and Glycine Treated Cells
One final alternative strategy for determining the localization of Spe2 is the
use of Proteinase K to degrade proteins protected by the thick mycobacterial cell
wall. Lysozyme and glycine treatment has been used in the literature to weaken
mycobacterial cell walls for applications such as spheroplast preparation and
genomic DNA extraction (59–61). Here, I applied this concept to make the cell wall
leaky, thus enabling Proteinase K accessibility to proteins normally protected by the
cell wall. I predicted that short treatment with Proteinase K would result in the
degradation of solely periplasmic proteins and that longer treatment would result in
the degradation of cytoplasmic proteins in addition to periplasmic proteins.
Pre-treatment of Spe2-HA expressing cells with lysozyme and glycine at 37°C
followed by treatment with or without Proteinase K resulted in the retention of the
cytoplasmic proteasome-associated ATPase Mpa (MSMEG_3902) (62) and the loss
of Spe2-HA with 1mg/ml Proteinase K treatment within the same Msm strain
(Figure 10). Interestingly, cells that were not treated with lysozyme and glycine had
similar trends in retention and degradation of Mpa and Spe2-HA compared with
lysozyme and glycine pre-treated cells, suggesting that lysozyme and glycine pretreatment was not required for Proteinase K access to internal proteins during this
experiment (Figure 10). Considering that Spe2-HA is under the control of a heat
shock promoter, incubations at 37°C would mean Spe2-HA was overproduced by
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these cells. Such levels of Spe2-HA might explain why Spe2-HA requires 1mg/ml of
Proteinase K for complete degradation. Overall, these results reinforce that Spe2 is
not a cytoplasmic protein, as Spe2-HA was not retained in the same manner as the
cytoplasmic control Mpa.
Together, the results from these independent experiments provide
substantial evidence pointing to Spe2 localization to the periplasm, the site of
LM/LAM biosynthesis, and not the cytoplasm. Thus, the data reinforce our
hypothesis that Spe2 regulates the mannosyltransferases in this pathway.
3.2

Genetic Interaction of Spe2 with Elongation Mannosyltransferases
Preliminary data has shown that the deletion of Spe2 results in the
truncation of both LM and LAM, suggesting Spe2 might be a positive regulator of
either one or both of the elongation mannosyltransferases in LM/LAM biosynthesis:
unknown mannosyltransferase and MptA. Genetic manipulation was utilized to
better understand the relationship between Spe2 and the enzymes involved in this
biosynthetic pathway.

3.2.1 Comparative LM/LAM Analysis of MptA Knockdown in a Δspe2 Strain
We have previously generated a strain of Msm that has a tetracycline (tet)-off
inducible knockdown system for conditionally shutting off MptA expression (11),
herein referred to as WT/MptA KD. In this system, a reverse tet repressor (revTetR)
responsive promoter (tetO) was introduced in front of the endogenous MptA
(MSMEG_4241) gene by homologous recombination. An episomal copy of the
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revTetR was then introduced. Upon the addition of anhydrotetracycline (atc), atc
binds to revTetR, which then binds to tetO. This in turn blocks transcription of mptA,
thereby diminishing further MptA production.
To examine the role of Spe2 in the LM/LAM biosynthetic pathway (Figure
11), the knockdown system described above was introduced into a Δspe2 Msm
strain, herein referred to as Δspe2/MptA KD (Figure 12a). Western blotting
confirmed that with the addition of atc, MptA was knocked down by the time the
cells reached logarithmic phase (Figure 12b).
I then visualized LM and LAM extracts as previously described (11). Without
the addition of atc, LM and LAM appeared similar to WT and Δspe2 (see Figure 5) in
the WT/MptA KD and Δspe2/MptA KD strains, respectively (Figure 13). Conversely,
with the addition of atc, both WT/MptA KD and Δspe2/MptA KD strains showed
smaller LM and little to no LAM (Figure 13). Interestingly, both knockdown mutants
show an accumulation of LM over time (Supplemental Figure 4).
3.2.2 MALDI-TOF Analysis of LM Products in the Δspe2/MptA Tet-Off Strain
In order to determine whether these intermediate LM species are similar in
size and structure, matrix assisted laser desorption – time of flight (MALDI-TOF)
mass spectrometry of octyl-sepharose purified LM/LAM extracts was performed at
the UMass Amherst Mass Spectrometry Center. Indeed, the mass spectrum of LM
from the Δspe2/MptA KD strain was identical to that of the WT/MptA strain (Figure
14). Despite the presence of sinapinic acid (SA) adducts originating from the matrix,
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these spectra match theoretical atomic masses in addition to previously published
spectra (11) once the SA adducts are subtracted from the recorded mass. Analysis of
butanol lipid extracts via HPTLC and subsequent chemical staining established that
no other changes in PIMs (Figure 15a) nor PI (Figure 15b) occur with the
knockdown of MptA. Together, these data indicate that the absence of Spe2 does not
interfere with PI, PIMs, nor LM/LAM biosynthesis upstream of MptA, thereby
suggesting Spe2 acts either at or downstream of MptA activity.
3.3

Protein-Protein Interactions of Spe2
From the previous sections, I can draw the conclusion that Spe2 is likely a
periplasmic protein that acts downstream of the unknown elongase in LM
biosynthesis. MptA is responsible for elongating LM to its mature length, and thus,
Spe2 might interact with MptA directly, indirectly, or through other targets to
enhance its activity. In order to elucidate potential protein-protein interactions with
Spe2, native PAGE and co-immunoprecipitation techniques were implemented.

3.3.1 Native PAGE Analysis of Spe2-HA
Native PAGE is a technique that avoids the use of the traditional reducing
agents, such as SDS and DTT. Such omission of these agents enables the visualization
of protein complexes and/or proteins in their native conformations that would have
otherwise been disrupted. Accordingly, lysate from the Spe2-HA expressing Msm
strain was run on a 12% native gel under reducing and non-reducing conditions
(Figure 16a). Varying percentages of TritonX-100 was added to promote
mobilization of native proteins during native PAGE. Under reducing conditions and
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regardless of the percentage of TritonX-100 added, Spe2-HA appears as a single
band at just below 37 kDa (Figure 16a). However, under non-reducing conditions,
Spe2-HA is seen as both the ~37 kDa band in addition to smears above this
molecular weight, suggesting the presence of protein-protein interactions involving
Spe2-HA (Figure 16a). Interestingly, the addition of 1%TritonX-100 diminishes this
smear. Next, I sought to examine the IP of Spe2-HA under native conditions under
the premise that IP is more likely to enrich true Spe2-protein interactions. Anti-HA
IP eluates were run on native PAGE alongside lysate with either 0.5 or 1% TritonX100. Surprisingly, no higher molecular weight bands were seen in the eluates either
under reducing or non-reducing conditions (Figure 16b). However, the higher
molecular weight bands, particularly the ~75 kDa band, was reproduced in lysate
under non-reducing conditions as seen in Figure 16a (Figure 16b), implicating that
these are not likely to be random artifacts.
To better understand why the eluates lose these higher molecular weight
bands seen in lysate under non-reducing conditions, I considered that weak or
transient interactions with Spe2 might be disrupted during the IP procedure. In light
of this, NaCl was removed from IP buffers. As a reference, 150mM NaCl (the same
concentration as in the IP buffers) was added to lysate, which does not originally
contain NaCl. Indeed, the removal of NaCl in eluates under non-reducing conditions
results in the visualization of higher molecular weight smears, in addition to
reduced signal at the ~37kDa band (Figure 17a). This phenotype suggests Spe2 in
its native state is potentially interacting with another protein.
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3.3.2 Analysis of Potential Protein Co-Immunoprecipitation with Spe2-HA
Since the higher molecular weight bands are only seen in non-reducing
conditions in native PAGE, it seemed reasonable to investigate potential binding
partners.

To

determine

whether

Spe2

physically

interacts

with

mannosyltransferases in the LM/LAM biosynthetic pathway, anti-HA IP eluates
were probed for MptA, the elongase, and MptC, the branching mannosyltransferase.
Interestingly, MptA did not co-immunoprecipitate (co-IP) with Spe2 in either
reducing or non-reducing conditions (Figure 17b, upper panel). However, western
blot analysis of anti-HA (-) NaCl eluates under both reducing and non-reducing
conditions showed that multiple bands appear when probed for MptC (Figure 17b,
lower panel).
Due to the presence of multiple bands in the anti-MptC western blot analysis of antiHA eluates, I sought to confirm the specificity of both the higher molecular weight
smears/bands from lysate and eluates. To do so, I probed WT lysate and anti-HA IP
of WT lysate. When probed with anti-HA, both lysates from WT and the Spe2-HA
expressing strain produce similar banding patterns, including the ~75kDa band
seen previously (Figure 16), under a range of reducing and non-reducing conditions
(Figure 18a). Similarly, when probing for MptC in WT and Spe2-HA anti-HA eluates,
similar

banding

patterns

appear

when

NaCl

is

removed

from

the

immunoprecipitation buffers (Figure 18b, right panel). These nearly identical
binding patterns in both lysates and eluates indicate that the high molecular weight
smears and bands are non-specific and unlikely to be true Spe2 binding partners.
27

However, two bands do appear to be specific to the Spe2-HA anti-HA eluate when
probing for MptC (Figure 18b, right panel), and may indicate co-imunoprecipitation
with Spe2-HA.
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CHAPTER 4
DISCUSSION
The mycobacterial cell wall is an extremely potent barrier against
environmental stresses, including the host immunity and antibiotics (11, 63).
Modulation of cell envelope components—which requires intimate knowledge of
the respective biosynthetic pathways—appears to be a promising strategy for
fighting mycobacterial infection.
The biosynthetic pathway of the abundant glycolipids LM and LAM is largely
unraveled in terms of the biosynthetic enzymes involved. However, its regulation is
still unclear. Here, I describe a novel mycobacterial protein termed Spe2, which
plays a role in the regulation of LM biosynthesis.
First, I suggest Spe2 is a periplasmic protein through a number of
biochemical techniques. IP of Spe2 in lysate requires the addition of mild detergent,
which is not needed for the IP of cytoplasmic proteins (Figure 7). Additionally, Spe2
is not surface exposed, as IP and Proteinase K treatment of whole, intact cells did
not recover (Figures 8 and 9). Moreover, Proteinase K treatment in PBS starved cells
with or without lysozyme and glycine cell wall weakening of whole, intact cells was
successful in degrading Spe2 but not the cytoplasmic protein Mpa within the same
Msm strain (Figure 10). Unfortunately, the intended outer membrane protein
control Mtb12 was problematic throughout these experiments. IP of Mtb12-FLAG
from intact cells was successful during the optimization of the technique but failed
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when attempted months later alongside Spe2-HA and GlnA1-HA. While Proteinase K
treatment of Mtb12-FLAG in intact cells generated the desired phenotype, but only
when a small amount of sample was analyzed by SDS-PAGE (Figure 9), this shows
that Proteinase K degradation of surface exposed proteins might be working, but
somehow cannot completely degrade Mtb12-FLAG. A potential explanation for this
phenomenon includes taking into consideration the small size of the protein, and
the over-expression of Mtb12-FLAG. Mtb12 in its mature form is 13.3 kDa (64),
which may be too small for Proteinase K to access in the outer membrane.
Additionally, Mtb12 was discovered in Mtb as a culture filtrate protein, meaning the
protein can be found abundantly in the supernatant of Mtb cultures (64). It is
possible that Mtb12 is naturally produced in high abundance, and in addition to heat
shock promoter-induced over-expression, can be constitutively produced by the
cell. As a result, the detection of Mtb12-FLAG in western blots during Proteinase K
treatments, for example, could potentially be due to cytoplasmic pools of Mtb12FLAG, or newly replaced Mtb12-FLAG at the surface of the cell. Thus, an alternative
approach could be to utilize Mtb12-FLAG as a positive control for proteins secreted
out of the cell. If Mtb12-FLAG, but not Spe2-HA is found in the supernatant of
cultures, one might expect Spe2 is not externally secreted, and thus, more likely to
be periplasmically localized.
A study by van der Woude et al. 2013 describe a method to selectively extract
outer membrane proteins from Mycobacterium marinum with OBG. In their
technique, whole cells were subjected to lysis and ultracentrifugation to isolate a
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cell envelope fraction. This fraction was further subjected to OBG treatment, in
which the supernatants were claimed to contain the extracted outer membrane
proteins. However, it is important to note the limitations of this study. The caveat of
this technique is that OBG does not appear to specifically extract outer membrane
proteins. Using mass spectrometry analysis of cell envelope fraction OBG extracts,
the authors claim that over 90% of predicted outer membrane proteins found in the
cell envelope fraction were extracted. Conversely, only 30% of predicted inner
membrane proteins were extracted by OBG. However, an even greater 31-89% of
proteins extracted by OBG were undefined (which the authors termed “middle”) in
terms of their localization (65). OBG has also been used to permeabilize the outer
membrane of Msm, and similar members of this family of detergents have been used
to selectively extract the Msm outer membrane porin MspA (57). The difficulty in
isolating mycobacterial outer membrane proteins has been reviewed in the
literature (66). It is likely that membrane proteins may not be exclusively found in
the outer membrane, and features of mycobacterial outer membrane-specific
proteins may have unknown unique properties not previously seen in Gramnegative outer membranes.
Despite the lack of an efficient outer membrane protein control, the data
from previous experiments such as the sucrose gradient showing that Spe2 localizes
to the PM-CW (Figure 6), as well as the experiments using cytoplasmic protein
controls described in this study, all support the concept of Spe2 as a periplasmic
protein by suggesting Spe2 is neither an outer membrane nor cytoplasmic protein.
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It must be noted that these results could be interpreted as Spe2 being an
inner membrane protein. In accordance with this interpretation, Spe2 must be an
inner membrane protein with a periplasmic active face in order to be able to
interact with the LM/LAM biosynthetic pathway. The rationale is, as mentioned
earlier, that the deletion or mutation of Spe2 results in the shift of both LM and LAM
(Figures 4 and 5), which clearly indicates its association with the LM/LAM
biosynthetic pathway. One approach to distinguish between periplasmic and inner
membrane localization is to examine whether the signal sequence of Spe2 is cleaved.
If this sequence is not cleaved, Spe2 would remain in the inner membrane postexport. However, if the sequence is cleaved, Spe2 is likely periplasmic. A strategy to
determine this is to visualize the loss of an N-terminal epitope tag on Spe2-HA (i.e.
T7-Spe2-HA), which would indicate the loss of the signal sequence. In either case,
Spe2 must be able to interact with the components of this pathway, and its
periplasmic or inner membrane localization supports such a role.
In this study, I demonstrate that Spe2 acts downstream of the unknown
elongase of LM biosynthesis by showing that same-size LM intermediates
accumulate in both WT/MptA KD and Δspe2/MptA KD strains (Figure 13). Since no
other changes in the precursors of this pathway, such as PI and PIMs are seen
(Figure 15), and the mass spectra are identical (Figure 14), the LM intermediates in
WT/MptA KD and Δspe2/MptA KD must be the same intermediate. However, it is
important to note that I could not—in my own hands—analyze larger species of LM
or LAM, such as WT LM, by MALDI-TOF. It is possible I could not use MS to detect
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slightly larger species of LM not visible by SDS-PAGE and ProQ Emerald due to this
limitation. Interestingly, polysaccharide species of lower mass are seen in both
spectra (Figure 14). These also have the same distance between peaks (162 mass
units) and form a high intensity curve not unlike that of LM. Based on the masses,
this curve could potentially be a range of PIM species, such as AcPIM6 and AcPIM4.
Comparisons of these spectra with those of butanol lipid extracts analyzed under
the same conditions might confirm whether this is the case.
Our hypothesis is that Spe2 acts during the elongation of LM, as Δspe2
LM/LAM has smaller LM and LAM compared to WT (Figure 5), meaning Spe2
potentially modulates MptA activity. However, the data presented in this study, do
not provide enough evidence to distinguish whether Spe2 is active at the same stage
as MptA or downstream of MptA. It is likely Spe2 works upstream of LAM synthesis.
One interpretation of the small LM/LAM phenotype of Δspe2 is that Spe2 promotes
the maturation of LM, which in turn, affects the maturation of LAM. If the mutant
begins LAM biosynthesis with smaller LM (compared to WT), the resulting LAM is
likely smaller as well.

MptC is another mannosyltransferase involved in LM

biosynthesis. This enzyme has been suggested to work simultaneously with, in
addition to upstream of, MptA. Thus, MptC might also be affected by Spe2 activity.
Moreover, the over-expression of MptC has been shown to shift LM/LAM size
similar to that of Δspe2 (38). Therefore, it would be interesting to compare
WT/MptA KD/MptC KD with Δspe2/MptA KD/MptC KD and examine the effect of
the double knockdowns, as Spe2 may somehow keep MptC activity in check.
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In an attempt to elucidate the function of Spe2, I explored potential proteinprotein interactions involving Spe2 and other enzymes in the LM biosynthetic
pathway—mainly MptA and MptC. Native PAGE has been successfully utilized in the
literature to identify components within a protein complex, particularly with twodimensional gels in which a protein complex is run on a native gel, the entire lane
cut out, and subsequently run on SDS-PAGE to separate the individual components
of the complex (67). Instead, I opted to examine the appearance of higher molecular
weight bands or smears when Spe2-HA is run on a native gel lacking SDS. Although
the presence of smears above the expected molecular weight of Spe2-HA was visible
in non-reducing conditions but lacking in reducing conditions (Figures 15 and 16),
these smears were also present when WT lysate or immunoprecipitation eluates
were run under the same conditions (Figure 17). The seemingly promising results
from the removal of NaCl—with the intent to visualize weak or transient
interactions—in the immunoprecipitation buffers also increased non-specificity
(Figures 16 and 17). However, when probing anti-HA eluates for MptC, two bands
appeared to be specific co-immunoprecipitation with Spe2-HA, since neither of the
two bands were seen in the WT lysate anti-HA IP control (Figure 18b). Although
Spe2 may be interacting with MptC. I did not further examine this possibility. The
results are interesting since, as mentioned earlier, the overexpression of MptC
results in smaller LM and LAM similar to that of the Δspe2 mutant (38). In light of
this connection, Spe2 may physically interact with MptC to negatively regulating its
activity and enable proper elongation of the mannan chain by MptA.
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Alternative, non-biased approaches were attempted but not fully optimized.
These attempts included silver staining of anti-HA immunoprecipitation eluates (not
shown) to visualize proteins that may have co-immunoprecipitated with Spe2-HA
and crosslinking using two crosslinkers: dithiobis [succinimidylpropionate] (DSP)
and formaldehyde (not shown) in the event that the required TritonX-100 for
immunoprecipitation of Spe2-HA from lysate simultaneously disrupts interactions
with the protein.
To further speculate on the function of Spe2, I must consider preliminary
data from my colleague Kathryn C. Rahlwes. Kathryn is developing a Spe2 binding
assay similar to an enzyme linked immunosorbent assay (ELISA) in which Spe2-HA
in the form of lysate, immunoprecipitation eluates, or purified Spe2-HIS from E. coli
is added to wells coated with lipids such as PIMs and LM from my MptA
knockdowns lacking LAM. In her system, she is detecting Spe2 binding to MptA
knockdown LM as well as AcPIM6. If this is indeed true, Spe2 might play a role in LM
biosynthesis by regulating the length of the mannan chain. One speculation is that
Spe2 is involved in steric control of the mannan chain. For instance, Spe2 might bind
to intermediate LM produced by unknown elongase and enable only MptA to access
the chain up a particular length. The idea of a molecular ruler which determines the
maximum chain length of these glycolipids is a novel concept in this field, and thus,
is particularly worth exploring further.
Mishra et al. 2008 demonstrate that MptB, the mannosyltransferase in the
related organism Corynebacterium glutamicum ATCC 13032, is essential for LM and
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LAM biosynthesis, as it mediates the initial elongation of LM (37). This group,
however, notes that its Msm homolog (MSMEG_3120) is not essential, suggesting
that other mannosyltransferases, including MptA, might compensate. Interestingly,
Kathryn has performed BLASTP for Spe2 in this strain of C. glutamicum and found
no homology. In light of these findings, one thought is that Spe2 might be involved in
transferring LM precursor to MptA, thereby providing it a substrate pool, and that in
the absence of MSMEG_3120 can compensate by transferring AcPIM4 or AcPIM6. In
this case, the lack of phenotype in the MSMEG_3120 deletion (37) could be
explained by the presence of Spe2, which is lacking in C. glutamicum ATCC 13032.
As mentioned previously, PIMs, LM, or LAM are essential in mycobacteria,
which implies their significant contribution to cell wall integrity. Of note, the pimE
suppressor mutants that also had mutations in spe2 that abolished its activity had
restored large colony morphology as seen in WT (Figure 3). Since ΔpimE results in
the accumulation of AcPIM4 (34) and Δspe2 results in smaller LM and LAM, the
combination of these two suggest mycobacteria lacking these two enzymes prefer to
accumulate these small glycolipids to somehow strengthen cell wall integrity. Thus,
Spe2 might be a key player in the biosynthesis of these cell envelope glycolipids,
which are critical for cell wall integrity as well as immunomodulation by
mycobacteria. These are both excellent targets for generating novel therapeutic
strategies to treat mycobacterial infections, thereby highlighting the importance of
further characterization of Spe2.
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Figure 1. Arrangement of the Mycobacterial Cell Envelope.
In addition to the canonical plasma membrane, mycobacteria possess an outer
membrane with an unusual repertoire of lipids and glycolipids. This
mycomembrane is covalently linked to the arabinogalactan-peptidoglycan (AG-PG)
layer via waxy mycolic acids. This mycolyl arabinogalacatan peptidoglycan (mAGP)
core is rather thick and confers resistance to harsh environmental stresses
encountered by the cells.
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Figure 2. PIMs/LM/LAM Biosynthetic Pathway in Mycobacterium smegmatis.
The biosynthesis of phosphatidyl-inositol (PI)-based glycolipids begin with the
mannosylation of PI to form the first major product AcPIM2, which is further
extended to form the intermediate AcPIM4. At this point, AcPIM4 can feed into
AcPIM6 biosynthesis or LM/LAM biosynthesis. These end products are assumed to
be transported into the outer membrane by unknown mechanisms. Essential
enzymes are shown in yellow. EmbC, which is essential in Mycobacterium
tuberculosis, but not in Mycobacterium smegmatis (Msm), is denoted with an
asterisk.
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Figure 3. Sequencing of S1, S10, and S22 reveals mutations in unannotated gene
spe2.
Whole genome sequencing of pimE suppressor mutants S1, S10, and S22 revealed
point mutations in S1 and S10, in addition to a 2 kb transposon insertion in S22,
within the same unannotated gene. The point mutations, shown in red, are in
conserved regions of the protein. (Rahlwes et al. in preparation)
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Figure 4. S1, S10, and S22 have shifts in LM and LAM that are restored by
complementing with Spe2.
(a) High performance thin layer chromatography (HPTLC) of butanol lipid extracts
containing PIMs. (b) 15% SDS-PAGE followed by ProQ Emerald 488 glycan staining.
These pimE suppressor mutants have similar shifts (smaller) LM and LAM (b),
which is restored to the WT phenotype upon complementation with Spe2 (b), the
gene that all three mutants had mutations in. However, no changes in PIMs (a) were
seen, indicating the specific effect of these mutations in Spe2 on LM/LAM. (Rahlwes
et al. in preparation)
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Figure 5. Δspe2 LM/LAM is restored upon complementation.
15% SDS-PAGE followed by ProQ Emerald 488 glycan staining. Deletion of Spe2
results in a similar shift in LM/LAM as seen in the suppressor mutants.
Complementation of Spe2 with Spe2-HA under various promoters shows the
restoration of WT LM/LAM, thereby implicating the relationship between Spe2 and
LM/LAM biosynthesis. (Rahlwes et al. in preparation)
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Figure 6. Spe2-HA localizes to the PM-CW.
Sucrose density gradient fractionation shows that Spe2-HA localizes to the plasma
membrane tightly associated with cell wall (PM-CW) and not to the mycobacterial
membrane domain (MMD, also known as the PMf). Expected molecular weights:
Spe2-HA, 29.5 kDa; PimB’, 41.4 kDa; MptC, 48.2 kDa. (Rahlwes et al. in preparation)
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Figure 7. Spe2 is inaccessible to α-HA beads in cell lysate without the presence of
mild detergent.
(a) Schematic of the expected results from immunoprecipitation (IP) of whole cell
lysate generated from a Spe2-HA expressing Msm strain or from a GlnA1-HA
expressing Msm strain using α-HA agarose beads with or without 1% TritonX-100 in
the IP buffer. Spe2 is only accessible to the α-HA agarose beads due to the
solubilization of the inner membrane when TritonX-100 is present (a, right). (b) αHA western blot of the IP outlined in (a). Inputs are ¼ of the amount used during IP.
Spe2-HA is only pulled down when TritonX-100 is present in the system, whereas
GlnA1-HA is pulled down under both conditions. Expected molecular weights: Spe2HA, 29.5 kDa; GlnA1-HA, 54.6 kDa.
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Figure 8. Spe2-HA is not immunoprecipitated from intact cells.
Lysate or whole cells from a Spe2-HA expressing strain was immunoprecipitated
using anti-HA agarose beads in the presence or absence of 1% TritonX-100 (a). In a
different immunoprecipitation (IP) system, using Protein A magnetic beads, neither
GlnA1-HA (b, upper arrow) nor Spe2-HA (b, bottom arrow) were
immunoprecipitated from whole, intact cells. Conversely, Mtb12-FLAG was
immunoprecipitated from whole cells, suggesting that Spe2-HA is not surface
exposed. The band seen at ~75 kDa is the heavy chain of α-HA antibody and the
band at ~ 25 kDa is the light chain of the α-HA antibody, which can remain in the
eluate of the magnetic bead IP system. Inputs were ¼ of the amount used during IP
and appears faint due to poor western blotting detection. Expected molecular
weights: Spe2-HA, 29.5 kDa; GlnA1-HA, 54.6 kDa; Mtb12-FLAG, 13.3 kDa (64).
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Figure 9. Protease accessibility in intact cells.
Intact cells or lysate from cells expressing Mtb12-FLAG, Spe2-HA, or GlnA1-HA were
subjected to Proteinase K treatment at 37°C. Proteins from intact cells were
recovered by incubation with 1% SDS at 37°C for 30 minutes. After 1 hour of
1mg/ml Proteinase K treatment of lysate, all three proteins were completely
degraded (a and b). In intact cells, Spe2-HA and GlnA1-HA were not recovered (b).
Recovery of proteins from intact cells by bead-beating lysis (c) show that Mtb12FLAG, in addition to Spe2-HA and GlnA1-HA, are maintained up to 2 hours of
treatment with Proteinase K. A non-specific band at 37 kDa is occasionally seen in
(b) during 1:1000 incubations with primary and secondary antibody. Input was 1.8
mg, with Mtb12-FLAG in (c) as the exception with an input of 0.9 mg. Expected
molecular weights: Spe2-HA, 29.5 kDa; GlnA1-HA, 54.6 kDa; Mtb12-FLAG, 13.3 kDa.
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Figure 10. Lysozyme and glycine weakening of the cell wall.
Whole cells from log phase were incubated in PBS or PBS containing 50 µg/ml of
lysozyme and 1.2% glycine for 3.5 hours, followed by treatment with or without
Proteinase K at the following concentrations: 0.1 mg/ml or 1 mg/ml. Spe2-HA is
retained in whole cells when treated with 0-0.1 mg/ml of Proteinase K. Conversely,
the addition of 1 mg/ml Proteinase K simultaneously results in the loss of Spe2-HA
and the retention of the cytoplasmic protein Mpa. Expected molecular weights:
Spe2-HA, 29.5 kDa; Mpa, 68 kDa.
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Figure 11. Rationale for generating an inducbile MptA knockdown strain of M.
smegmatis in Δspe2 background.
Predicted sizes (number of mannoses) of LM in a Spe2 deletion strain (a and b) or
MptA inducible knockdown in the Δspe2 background (c and d) of Msm. If Spe2
enhances the activity of unknown elongase (a or c) or MptA (b or d) in the WT
background, the terminal LM product, which is slightly smaller than mature LM,
accumulates when only spe2 is deleted (a and b). However, when knocking down
MptA in the Δspe2 background, the final LM product that accumulates is detectably
larger when Spe2 interacts with MptA (d) compared to when it interacts with the
unknown elongase (c).
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Figure 12. Schematic of inducible MptA knockdown.
Using the MptA knockdown system established by Fukuda et al. 2013, the addition
of anyhdrotetracycline (atc) can halt MptA transcription. (a) A revTetR responsive
promoter (TetO) was introduced immediately before mptA by homologous
recombination into WT or Δspe2 Msm strains. The revTetR was subsequently
introduced episomally. (b) Western blot confirmation of MptA knockdown by log
phase. WT lysate (input of 1.8 mg) was used as a western blot positive control.
Expected molecular weights: MptA, 54.3 kDa.
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Figure 13. Lipomannan (LM) of identical size accumulate in the MptA knockdowns.
MptA knockdown was induced through stationary phase (44 hours) with a final
concentration of 40 ng/ml atc. LM and LAM from each strain were extracted by
chloroform/methanol (2:1), followed by chloroform/methanol/water (2:1:0.8), and
then hot phenol. Extracts were diluted for better visualization of distinct LM/LAM
species, then run on 20% SDS-PAGE and visualized by ProQ Emerald 488
glycoprotein staining.
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Figure 14. MALDI-TOF MS of LM from MptA knockdowns.
MptA knockdown LM/LAM extracts from stationary phase were further purified
with octyl-sepharose and analyzed by MALDI-TOF mass spectrometry. Spectra of
WT/MptA KD (upper panel) and Δspe2/MptA (lower panel), shown with sinapinic
acid adducts, are identical. The number of mannoses (each addition of mannose
corresponds with 162 mass unit intervals) are indicated above each relevant peak.
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Figure 15. No changes in LM precursors are identified in the MptA knockdowns.
Butanol lipid extractions were run on HPTLC with chloroform-methanol-13M NH3water (180:140:9:9:23) as the solvent. Chemical staining and analysis of the
subsequent migrations of PIMS (a) and phospholipids (b) are well-established. The
staining of (a) PIMs by orcinol or (b) phospholipids by molybdenum blue confirm
that no significant changes in PIMs (a) nor PI (b) occur with the knockdown of
MptA.
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Figure 16. Comparisons of Spe2-HA under reducing and non-reducing conditions on
native PAGE.
Native PAGE analysis of (a) lysate or (b) anti-HA immunoprecipitation (IP) eluates
originating from a Spe2-HA expressing strain of Msm. Samples were run on a 12%
native gel with reducing (containing DTT and SDS) or non-reducing (contains no
DTT nor SDS) loading buffers. 0, 0.1, 0.5, or 1% TritonX-100 was added to samples
to promote protein migration through the gel. Expected molecular weights: Spe2HA, 29.5 kDa.
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Figure 17. Native PAGE analysis of anti-HA eluates with or without NaCl.
Lysate or anti-HA IP eluates from a Msm strain expressing Spe2-HA were run on
12% native gels under reducing or non-reducing conditions in the presence of
TritonX-100. (a) Comparison of the presence or absence of NaCl in samples. (b)
Analysis of potential co-immunopreciptiation of MptA or MptC with Spe2-HA during
anti-HA immunoprecipitation. The expected migration of MptA and MptC are
highlighted with arrows. Expected molecular weights: Spe2-HA, 29.5 kDa; MptA,
54.3 kDa; MptC, 48.2 kDa.
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Figure 18. Native PAGE with WT controls shows non-specific binding.
Native PAGE analysis of (a) lysate and (b) anti-HA IP eluates generated from WT or
Spe2-HA expressing strains of Msm. (a) A range of reducing and non-reducing
loading buffers containing different combinations of DTT or SDS additives was
utilized to compare lysates. Analysis of potential MptA or MptC co-IP with Spe2-HA
during anti-HA IP with or without the presence of salt (NaCl). Probing for MptC in
anti-HA IP eluates (b, right panel) shows both non-specific bands in both WT and
Spe2-HA lysate IP. However, two bands at 50 kDa and 100 kDa appear to be specific
to the Spe2-HA lysate anti-HA IP, suggesting potential co-IP. Expected molecular
weights: Spe2-HA, 29.5 kDa; MptA, 54.3 kDa; MptC, 48.2 kDa.
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Supplemental Figure 1. Spe2-HA is pulled down in the presence of a number of
detergents.
Spe2-HA is pulled down in the presence of TritonX-100 (HEST), TritonX-100 with
NaDOC (HESD), and a combination of TritonX-100, NaDOC, and SDS (RIPA).
However, Spe2-HA is not pulled down without any detergent (HES).
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Supplemental Figure 2. Spe2-HA is not as effectively pulled down with OBG.
Spe2-HA is pulled down with both TritonX-100 and n-octyl-β-D-glucoside (OBG) in
lysate, however the pull down is less efficient with OBG. Spe2-HA is not pulled down
from intact cells with either detergent.
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Supplemental Figure 3. Immunoprecipitation of Mtb12-FLAG.
Mtb12-FLAG is pulled down with protein A magnetic beads with OBG when
incubated at room temperature for 0.5 or 1 hour, or at 4°C overnight (O/N).
Interestingly, Mtb12-FLAG is not pulled down after 2 hours of incubation at room
temperature.
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Supplemental Figure 4. MptA knockdowns in WT background and Spe2 deletion
background.
ProQ Emerald 488 glycan staining of LM and LAM on 20% SDS-PAGE. MptA was
knocked down with the addition of anhydrotetracycline (atc) during log phase (log),
stationary (stat), and late stationary (L-stat) growth in WT/MptA KD and
Δspe2/MptA KD strains.
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